(Q41428068)

English

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

scientific article published on 21 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Danielle P Porter

1

object named as

Danielle P Porter

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

Rima Kulkarni

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Todd Fralich

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Michael D Miller

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Kirsten L White

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

publication date

21 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

30-38

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

1 reference

https://api.crossref.org/works/10.1179%2F1528433614Z.0000000009

21 January 2018

Identifiers

10.1179/1528433614Z.0000000009

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41428068&oldid=2147111451"